• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康受试者口服、直肠及肌肉注射蒿甲醚的相对生物利用度:高效液相色谱法与生物测定法同步测定的应用

Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay.

作者信息

Teja-Isavadharm P, Nosten F, Kyle D E, Luxemburger C, Ter Kuile F, Peggins J O, Brewer T G, White N J

机构信息

Department of Immunology and Parasitology, US Army Medical Component, Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand.

出版信息

Br J Clin Pharmacol. 1996 Nov;42(5):599-604. doi: 10.1111/j.1365-2125.1996.tb00115.x.

DOI:10.1111/j.1365-2125.1996.tb00115.x
PMID:8951191
Abstract
  1. The pharmacokinetic and effect kinetic properties of oral (p.o.), intramuscular (i.m.), and intrarectal (i.r.) artemether (5 mg kg-1) were compared in a crossover study in eight healthy adult volunteers. Plasma concentrations of artemether (AM) and its active metabolite dihydroartemisinin (DHA) were measured by high performance liquid chromatography with reductive mode electrochemical detection (h.p.l.c.-ECD), and plasma antimalarial activity in vitro (effect) was assessed on the same samples by a sensitive bioassay (BA). 2. Artemether was absorbed rapidly after oral administration with a mean (95% CI) Cmax for the parent compound of 406 (249 to 561) nmol l-1 and for DHA of 1009 (639 to 1379) nmol l-1 with tmax values of 1.7 (1.2 to 2.2) and 1.8 (1.4 to 2.2) h respectively. The mean (95% CI) elimination half-life of AM was 2.6 (1.8 to 3.4) h and for DHA was 1.9 (1.4 to 2.4) h. Plasma concentration and effect profiles with h.p.l.c.-ECD and BA were similar suggesting that other unidentified bioactive metabolites contributed little to antimalarial activity in vivo. 3. Absorption was slower, more variable, and DHA concentrations were lower following the i.m. and i.r. routes of administration. The mean (95% CI) relative bioavailability compared with oral artemether in the 6 h following administration AUC (0.6h) was 25 (9 to 41)% following i.m. and 35 (10 to 60)% following i.r. artemether. 4. These data demonstrate that oral artemether undergoes extensive first pass metabolism to the more active metabolite DHA. Plasma antimalarial activity following oral administration is significantly greater than following i.m. administration. The i.r. route of administration provided similar bioavailability to i.m. injection but there was considerable variability in absorption following both routes. Further studies are needed to determine whether i.r. artemether would be an effective treatment of severe malaria in the rural tropics in situations where oral or parenteral administration is not possible.
摘要
  1. 在一项交叉研究中,对8名健康成年志愿者口服(p.o.)、肌肉注射(i.m.)和直肠内(i.r.)给予蒿甲醚(5毫克/千克)后的药代动力学和药效动力学特性进行了比较。采用还原模式电化学检测高效液相色谱法(h.p.l.c.-ECD)测定血浆中蒿甲醚(AM)及其活性代谢物双氢青蒿素(DHA)的浓度,并通过灵敏生物测定法(BA)对相同样本评估体外血浆抗疟活性(效应)。2. 口服给药后蒿甲醚吸收迅速,母体化合物的平均(95%可信区间)Cmax为406(249至561)纳摩尔/升,DHA为1009(639至1379)纳摩尔/升,tmax值分别为1.7(1.2至2.2)小时和1.8(1.4至2.2)小时。AM的平均(95%可信区间)消除半衰期为2.6(1.8至3.4)小时,DHA为1.9(1.4至2.4)小时。h.p.l.c.-ECD和BA测定的血浆浓度和效应曲线相似,表明其他未鉴定的生物活性代谢物对体内抗疟活性贡献不大。3. 肌肉注射和直肠内给药途径的吸收较慢、变异性更大,DHA浓度较低。给药后6小时内,与口服蒿甲醚相比,肌肉注射蒿甲醚的平均(95%可信区间)相对生物利用度AUC(0.6小时)为25(9至41)%,直肠内给药为35(10至60)%。4. 这些数据表明,口服蒿甲醚会广泛首过代谢为活性更强的代谢物DHA。口服给药后的血浆抗疟活性显著高于肌肉注射给药。直肠内给药途径与肌肉注射的生物利用度相似,但两种途径的吸收均存在相当大的变异性。需要进一步研究以确定在无法口服或胃肠外给药的情况下,直肠内蒿甲醚是否能有效治疗热带农村地区的重症疟疾。

相似文献

1
Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay.健康受试者口服、直肠及肌肉注射蒿甲醚的相对生物利用度:高效液相色谱法与生物测定法同步测定的应用
Br J Clin Pharmacol. 1996 Nov;42(5):599-604. doi: 10.1111/j.1365-2125.1996.tb00115.x.
2
Pharmacokinetics and bioavailability of oral and intramuscular artemether.蒿甲醚口服及肌肉注射的药代动力学和生物利用度
Eur J Clin Pharmacol. 1997;52(4):307-10. doi: 10.1007/s002280050295.
3
Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria.青蒿琥酯在非复杂性恶性疟口服或肌内注射后的生物利用度。
Antimicrob Agents Chemother. 2003 Dec;47(12):3795-8. doi: 10.1128/AAC.47.12.3795-3798.2003.
4
Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria.口服青蒿琥酯在健康志愿者和非复杂性恶性疟患者中的比较药代动力学和效应动力学
Am J Trop Med Hyg. 2001 Dec;65(6):717-21. doi: 10.4269/ajtmh.2001.65.717.
5
Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria.重症恶性疟患者中肌肉注射青蒿琥酯和蒿甲醚的比较药代动力学
Antimicrob Agents Chemother. 2004 Nov;48(11):4234-9. doi: 10.1128/AAC.48.11.4234-4239.2004.
6
The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats.双氢青蒿素、蒿甲醚、青蒿琥酯和青蒿酸在大鼠体内的药代动力学及生物利用度
J Pharm Pharmacol. 1998 Feb;50(2):173-82. doi: 10.1111/j.2042-7158.1998.tb06173.x.
7
Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteers.蒿甲醚在马来西亚健康志愿者中的单剂量药代动力学
Br J Clin Pharmacol. 1997 Apr;43(4):363-5. doi: 10.1046/j.1365-2125.1997.00573.x.
8
The disposition of intramuscular artemether in children with cerebral malaria; a preliminary study.脑型疟疾患儿肌内注射蒿甲醚的处置:一项初步研究。
Trans R Soc Trop Med Hyg. 1997 May-Jun;91(3):331-4. doi: 10.1016/s0035-9203(97)90097-3.
9
A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria.青蒿琥酯与蒿甲醚治疗急性恶性疟原虫疟疾的抗疟生物活性比较。
Br J Clin Pharmacol. 2001 Dec;52(6):655-61. doi: 10.1046/j.1365-2125.2001.01458.x.
10
Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients.疟疾患者直肠给予青蒿琥酯后青蒿琥酯和双氢青蒿素的群体药代动力学
PLoS Med. 2006 Nov;3(11):e444. doi: 10.1371/journal.pmed.0030444.

引用本文的文献

1
Artemisinin-resistant malaria.抗青蒿素疟疾
Clin Microbiol Rev. 2024 Dec 10;37(4):e0010924. doi: 10.1128/cmr.00109-24. Epub 2024 Oct 15.
2
Assessment of quantitative and semi-quantitative biological test methods of artesunate in vitro.评估青蒿琥酯在体外的定量和半定量生物测试方法。
Parasite. 2022;29:18. doi: 10.1051/parasite/2022019. Epub 2022 Mar 29.
3
Physical stability and release properties of lumefantrine amorphous solid dispersion granules prepared by a simple solvent evaporation approach.通过简单溶剂蒸发法制备的卤泛群无定形固体分散体颗粒的物理稳定性和释放特性。
Int J Pharm X. 2020 Jul 16;2:100052. doi: 10.1016/j.ijpx.2020.100052. eCollection 2020 Dec.
4
Dihydroartemisinin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cell by Upregulating Tumor Necrosis Factor via JNK/NF-B Pathways.双氢青蒿素通过JNK/NF-κB途径上调肿瘤坏死因子,抑制人肝癌细胞增殖并诱导其凋亡。
Evid Based Complement Alternat Med. 2019 Aug 25;2019:9581327. doi: 10.1155/2019/9581327. eCollection 2019.
5
Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in healthy adults.抗疟药物蒿甲醚新型舌下喷雾制剂在健康成年人中的药代动力学
Antimicrob Agents Chemother. 2015;59(6):3197-207. doi: 10.1128/AAC.05013-14. Epub 2015 Mar 23.
6
Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in African children with malaria.抗疟药物蒿甲醚新型舌下喷雾制剂在非洲疟疾患儿中的药代动力学
Antimicrob Agents Chemother. 2015;59(6):3208-15. doi: 10.1128/AAC.05014-14. Epub 2015 Mar 23.
7
Artesunate tolerance in transgenic Plasmodium falciparum parasites overexpressing a tryptophan-rich protein.富含色氨酸蛋白的转基因疟原虫对青蒿琥酯的耐受性。
Antimicrob Agents Chemother. 2011 Jun;55(6):2576-84. doi: 10.1128/AAC.01409-10. Epub 2011 Apr 4.
8
Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.在坦桑尼亚,采用青蒿琥酯和咯萘啶联合疗法治疗无并发症恶性疟原虫疟疾患儿时,青蒿琥酯和咯萘啶的群体药代动力学和药效学。
Antimicrob Agents Chemother. 2010 Nov;54(11):4780-8. doi: 10.1128/AAC.00252-10. Epub 2010 Aug 16.
9
First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone.新型青蒿素衍生物蒿甲醚在人体中的安全性、耐受性、药代动力学及体外抗疟药效学活性的首次评估。
Antimicrob Agents Chemother. 2008 Sep;52(9):3085-91. doi: 10.1128/AAC.01585-07. Epub 2008 Jun 16.
10
Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies.用于疟疾治疗的直肠用青蒿素:基于临床研究中个体患者数据的疗效与安全性综述
BMC Infect Dis. 2008 Mar 28;8:39. doi: 10.1186/1471-2334-8-39.